Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Cash Equivalents
Sonoma Pharmaceuticals Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Cash Equivalents
$2.4m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-4%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Equivalents
$3.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Pfizer Inc
NYSE:PFE
|
Cash Equivalents
$719m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is Sonoma Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
2.4m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Cash Equivalents amounts to 2.4m USD.
What is Sonoma Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-4%
Over the last year, the Cash Equivalents growth was -9%. The average annual Cash Equivalents growth rates for Sonoma Pharmaceuticals Inc have been -24% over the past three years , -18% over the past five years , and -4% over the past ten years .